The present disclosure provides improved compositions comprising rifabutin,clarithromycin, and clofazimine foruse in the treatment of Inflammatory Bowel Diseases. In one instance, thecompositions may comprise a formulation of rifabutin,clarithromycin, and clofazimine in a single dosage form, such as a capsule,tablet, etc., with one or more specific excipients.